Publications
Knowledge generated at IrsiCaixa is shared with the scientific community through the publication of articles in high impact scientific journals.
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.
A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
New emerging targets in cancer immunotherapy: the role of neoantigens.
Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection.
Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients.
HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic.
Production of HIV-1-based virus-like particles for vaccination: achievements and limits.
CD4 recovery is associated with genetic variation in IFNγ and IL19 genes.
NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal.